Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

NCT00030784 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

NETWORK

Sponsor class

Conditions

Sarcoma

Interventions

DRUG: ifosfamide
DRUG: pegylated liposomal doxorubicin hydrochloride

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC